Harmony Biosciences Hldgs Azioni (NASDAQ: HRMY)

Harmony Biosciences Hldgs (NASDAQ:HRMY) Azioni

HARMONY BIOSCIENCES HOLDINGS

Harmony Biosciences

Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.

Harmony Biosciences Hldgs

Harmony Biosciences Holdings, Inc. - Common Stock

Harmony Biosciences Holdings Inc

<p>Citigroup  analyst Andrew Kaplowitz   maintains Rockwell Automation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ROK#NYSE">ROK</a>) with a Buy and raises the price target from $283 to $327.</p>


News

Price Target

Analyst Ratings

Citigroup Maintains Buy on Rockwell Automation, Raises Price Target to $327

WIIM

SEDG

SolarEdge Technologies shares are trading higher. The company recently reported better-than-expected Q1 financial results and issued Q2 sales guidance above estimates.

<p>Citigroup  analyst Michael Rollins   maintains Cencora (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COR#NYSE">COR</a>) with a Buy and raises the price target from $330 to $355.</p>


Citigroup Maintains Buy on Cencora, Raises Price Target to $355

<p>Germany's <a href="https://www.benzinga.com/topic/germany-cannabis">cannabis landscape</a> continues evolving at a rapid pace. From extensive pharmacy access to a surge in cultivation associations, the country's dual-track model—medical and non-commercial adult use—has turned it into one of the most closely watched cannabis markets in the world.</p>
<p>Still, many in the industry argue that restrictive EU regulations are preventing Germany from reaching its full potential.</p>
<h3 class="wp-block-heading">1 In 7 Pharmacies Now Dispenses Medical Cannabis</h3>
<p>As reported by <a href="https://internationalcbc.com/more-than-1-out-of-every-7-german-pharmacies-offers-medical-cannabis/?utm_source=ICBC+Combined+List+Newsletter+and+Outreach&amp;utm_campaign=7599cd320e-EMAIL_CAMPAIGN_2025_05_05_06_44&amp;utm_medium=email&amp;utm_term=0_-7599cd320e-23726375">ICBC</a>, roughly 2,500 of Germany's 17,000 pharmacies now offer medical cannabis products—a dramatic expansion since legal access began in 2017. Patients can also order cannabis online with a private prescription and have it delivered directly to their homes.</p>
<p>According to the <strong>German Cannabis Business Association</strong> (BvCW), the country's legal medical cannabis revenue is now estimated at around half a billion euros annually.</p>
<p>Yet that number only scratches the surface of the market's potential. At ICBC Berlin, economist <strong>Beau Whitney</strong> presented data showing flower and extract sales dominate the German market due to a ban on edibles and other product formats. For comparison, U.S. 4/20 sales were only 41% flower, with the rest divided between vapes, <a href="https://www.benzinga.com/markets/cannabis/25/05/45263739/they-turned-fruit-bouquets-into-a-500m-a-year-businessnow-theyre-selling-thc-heres-why">edibles</a>, <a href="https://www.benzinga.com/markets/cannabis/25/04/44929611/why-pre-rolls-are-cannabis-most-profitable-format-from-california-to-canada">pre-rolls</a> and topicals.</p>
<p>The takeaway? Consumers who prefer smokeless options have limited legal choices in Germany, leaving the door open for the unregulated market.</p>
<h3 class="wp-block-heading">Germany's Cultivation Associations Are Growing Fast</h3>
<p>Meanwhile, the number of licensed cannabis cultivation associations continues to rise. As of early May, Germany had approved 211 of the 624 applications submitted nationwide since the member-based model went live in July 2024.</p>
<p>The associations—legal under EU health policy frameworks—allow registered members to collectively grow cannabis for personal use. Though not commercial in nature, they offer a legal alternative for adults seeking safe, regulated cannabis outside the pharmacy system.</p>
<p>For perspective, Malta—another EU member state with a similar model—has issued 19 permits for its 570,000 residents. Applying Malta's ratio to Germany's population of 84 million implies that over 2,800 associations could eventually be formed.</p>
<p>Still, much remains in flux. Only 25 German applications have been formally rejected so far and many approved groups are still navigating the setup phase.</p>
<h3 class="wp-block-heading">What's Next?</h3>
<p>Germany is already Europe's largest cannabis market, and interest from international operators and policymakers shows no sign of slowing. But experts say broader legalization—including more product categories and commercial access—is essential to meet patient demand and curb illicit activity.</p>
<p>As the BvCW notes, &#8220;the industry's revenue is now estimated at around half a billion euros"—but with edibles, national retail and broader exports still off-limits, the true ceiling remains far higher.</p>
<h3 class="wp-block-heading">Stocks To Watch</h3>
<p>Germany's expanding cannabis market has attracted significant investment from major publicly traded companies. Here are some key players:</p>
<ul>
<li><strong>Tilray Brands </strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>): Tilray operates a GMP-certified cultivation facility in Neumünster and has recently expanded its medical cannabis offerings in Germany, including new extract formulations and high-THC flower strains under the Tilray Craft brand.</li>
<li><strong>Aurora Cannabis</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACB#NASDAQ">ACB</a>): Aurora launched its first domestically grown medical cannabis brand, IndiMed, cultivated at its EU-GMP facility in Leuna. This move positions Aurora as one of the few companies with local production capabilities in Germany.</li>
<li><strong>Canopy Growth </strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGC#NASDAQ">CGC</a>): Canopy Growth has introduced its Tweed brand to the German medical cannabis market, expanding its product lineup with new strains through strategic partnerships with EU-based cultivators.</li>
<li><strong>Curaleaf Holdings</strong> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CURLF#OTC">CURLF</a>): Curaleaf has taken a majority stake in Germany&#8217;s Four 20 Pharma, enhancing its footprint in the European market and aiming to leverage Four 20 Pharma&#8217;s distribution network.</li>
<li><strong>High Tide</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HITI#NASDAQ">HITI</a>): High Tide initially planned to enter the German medical cannabis market through the acquisition of Purecan GmbH. However, the company is currently reevaluating this strategy and exploring alternative arrangements to establish a presence in Germany.</li>
</ul>
<p>Photo: Shutterstock</p>


Cannabis

Eurozone

CURALEAF HLDGS INC by Curaleaf Hldgs Inc.

CURLF

HITI

TLRY

Germany's Cannabis Industry Hits 500 Million Euros: 2,500 Pharmacies Now Dispense, 211 Grow Clubs Approved

<p><strong>Ark Invest </strong>CEO and Founder <strong>Cathie Wood </strong>is no stranger to loving companies that are founded and/or run by<strong> Elon Musk, </strong>with <a href="https://www.benzinga.com/24/12/42486618/heres-how-much-1000-invested-in-tesla-stock-today-will-be-worth-if-cathie-woods-price-prediction-comes-true-in-2029">her early bets </a>on <strong>Tesla</strong>, <strong>SpaceX </strong>and others.</p>
<p>The <strong>Ark Venture Fund</strong>, which <a href="https://www.benzinga.com/news/22/11/29524537/cathie-wood-invested-in-musks-twitter-takeover-how-you-can-get-a-stake-for-500">offers access </a>to private companies, added to its stake in a Musk company during the first quarter. This is in addition to SpaceX already being the fund&#8217;s top holding.</p>
<p><strong>What Happened:</strong> During the first quarter, the Ark Venture Fund reinvested in <strong>X Corp</strong>, the company previously known as Twitter. That new stake converted into a position in <strong>xAI</strong>, Musk's artificial intelligence company, thanks to a<a href="https://www.benzinga.com/tech/25/03/44549314/elon-musk-acquires-his-own-social-media-platform-x-through-xai-in-33-billion-deal-says-combined-entity-now-worth-80-billion"> merger of the two companies.</a></p>
<p>The merger valued xAI at $80 billion and X at $33 billion to create the combined xAI Holdings Corp company.</p>
<p>Ark's quarter summary <a href="https://www.ark-funds.com/articles/venture-fund/ark-venture-q1-2025-update">letter </a>said the combined company will integrate the "cutting-edge foundational models" of xAI with X's user base of more than 600 million people. The letter said the merger could "unlock a platform that blends real-time communication with AI-enhanced discovery, truth-seeking, and personalized knowledge delivery."</p>
<p>"We believe this merger will be a significant catalyst for consumer AI adoption and foundational model monetization," the letter said.</p>
<p>Here are the fund's top 10 <a href="https://www.ark-funds.com/funds/arkvx?utm_source=adwords&amp;utm_medium=ppc&amp;hsa_acc=2895577906&amp;hsa_cam=22423858049&amp;hsa_src=x&amp;hsa_net=adwords&amp;hsa_ver=3&amp;gad_source=1&amp;gad_campaignid=22420004586&amp;gbraid=0AAAAADoxXfLelVrScBMGodSi-ZYIxu_IE&amp;gclid=Cj0KCQjwrPHABhCIARIsAFW2XBMOnMDrFcbeL01AQJvT4M3Ii56kvRlmTf8Mr1iE4ejZk1soqgaYnMYaAnqGEALw_wcB">holdings </a>as of April 30, with the percent of the fund's assets:</p>
<ol>
<li><strong>SpaceX</strong>: 14.6%</li>
<li><strong>OpenAI</strong>: 7.5%</li>
<li><strong>X.AI</strong>: 6.3%</li>
<li><strong>Hammerspace</strong>: 3.6%</li>
<li><strong>Anthropic</strong>: 3.5%</li>
<li><strong>Lambda Labs</strong>: 3.5%</li>
<li><strong>Blockdaemon</strong>: 3.3%</li>
<li><strong>Epic Games</strong>: 2.6%</li>
<li><strong>Shield AI</strong>: 2.5%</li>
<li><strong>Radiant Industries</strong>: 2.4%</li>
</ol>
<p>SpaceX and xAI, two Musk-related companies are two of the top three holdings, while OpenAI, which Musk was also involved with previously, ranks second.</p>
<p>Together, the stakes in SpaceX and xAI represent 20.9% of the fund's assets.</p>
<p><strong>Read Also: <a href="https://www.benzinga.com/top-stories/24/08/40423891/buffett-musk-wood-cuban-or-ackman-who-do-investors-trust-most-with-life-savings-poll-shows-it-isnt-e">Buffett, Musk, Wood, Cuban Or Ackman: Who Do Investors Trust Most With Life Savings? Poll Shows It Isn&#8217;t Even Close</a></strong></p>
<p><strong>Other Investments</strong>: The Ark Venture Fund made several investments in sectors it believes in for the long-term as part of its strategy to find innovative companies.</p>
<p>"Amid the volatility and uncertainty dominating the opening months of the year, our conviction in the opportunity to invest in disruptive innovation remains strong," Ark said.</p>
<p>In the Robotics sector, Ark Venture Fund invested in <strong>Apptronik </strong>and <strong>Kodiak Robotics</strong>. The company said Apptronik is addressing global labor shortages and working toward a future where robots and humans can work together. Kodiak Robotics is an <a href="https://www.benzinga.com/markets/equities/25/04/44809515/george-soros-cathie-wood-backed-autonomous-trucking-firm-kodiak-robotics-set-to-go-public-via-spac-merger-to-tap-4-trillion-market">autonomous trucking company </a>founded by<strong> Don Burnette,</strong> who was a co-founder of <strong>Uber's </strong>self-driving truck division.</p>
<p>"As autonomous logistics scales, Kodiak is well positioned to lead in operational efficiency and safety."</p>
<p>The Ark Venture Fund also made its first investment in the nuclear energy space with an investment in <strong>Radiant Nuclear</strong>. The letter says Radiant Nuclear was founded by former SpaceX engineers.</p>
<p>Semiconductor company <strong>Groq </strong>and cloud infrastructure company<strong> Lambda Labs</strong> were new investments by the fund for the next-generation internet sector.</p>
<p>"With strong momentum in both government and enterprise sectors, Groq is emerging as a core player in real-time AI computer infrastructure."</p>
<p>Other investments by Ark in the quarter also include fintech <strong>Revolut </strong>and <strong>Generate:Biomedicines </strong>and <strong>Lila Sciences</strong> in the AI sciences space.</p>
<p>"We are energized by what's ahead in 2025 and encouraged by the growth and engagement of our investor community."</p>
<p><strong>Read Next: </strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/markets/mutual-funds/24/04/38213342/cathie-wood-ark-invest-announce-stake-in-openai-heres-how-you-can-get-exposure-to-chatgpt-pa">Cathie Wood, Ark Invest Announce Stake In OpenAI: Here&#8217;s How You Can Get Exposure To ChatGPT Parent, X (Twitter), SpaceX, Discord, Epic Games</a></strong></li>
</ul>
<p><em>Photo: Shutterstock</em></p>


Financing

Tech

After SpaceX, Cathie Wood Bets Big on Elon Musk's xAI

<p>Citigroup  analyst Andrew Kaplowitz   maintains Emerson Electric (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EMR#NYSE">EMR</a>) with a Buy and raises the price target from $119 to $127.</p>


Citigroup Maintains Buy on Emerson Electric, Raises Price Target to $127

<p>Citigroup  analyst Andrew Gardiner   maintains ARM Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARM#NASDAQ">ARM</a>) with a Buy and lowers the price target from $200 to $170.</p>


Citigroup Maintains Buy on ARM Holdings, Lowers Price Target to $170

<p>Citigroup  analyst Ygal Arounian   maintains Redfin (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDFN#NASDAQ">RDFN</a>) with a Neutral and raises the price target from $7.3 to $9.2.</p>


RDFN

Citigroup Maintains Neutral on Redfin, Raises Price Target to $9.2

<p>Citigroup  analyst Tyler Radke   maintains Palantir Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>) with a Neutral and raises the price target from $110 to $115.</p>


PLTR

Citigroup Maintains Neutral on Palantir Technologies, Raises Price Target to $115

Pagaya Technologies shares are trading higher after the company on Wednesday reported better-than-expected Q1 financial results, issued Q2 sales guidance above estimates, and raised its FY25 sales guidance

<p>Citigroup  analyst Asiya Merchant   maintains CDW (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDW#NASDAQ">CDW</a>) with a Neutral and raises the price target from $160 to $180.</p>


Citigroup Maintains Neutral on CDW, Raises Price Target to $180

BMBL

Bumble shares are trading higher following mixed Q1 financial results.

<p>Ocugen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCGN#NASDAQ">OCGN</a>) will release its quarterly earnings report on Friday, 2025-05-09. Here's a brief overview for investors ahead of the announcement.</p>
<p>Analysts anticipate Ocugen to report an <strong>earnings per share</strong> (EPS) of $-0.06.</p>
<p>Investors in Ocugen are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.</p>
<p>It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.</p>
<h3>Earnings History Snapshot</h3>
<p>The company's EPS missed by $0.00 in the last quarter, leading to a 9.96% increase in the share price on the following day.</p>
<p>Here's a look at Ocugen's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.05</td>
<td>-0.05</td>
<td>-0.05</td>
<td>-0.06</td>
<td>-0.06</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.05</td>
<td>-0.05</td>
<td>-0.04</td>
<td>-0.05</td>
<td>-0.04</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>10.0%</td>
<td>-9.0%</td>
<td>-2.0%</td>
<td>15.0%</td>
<td>-9.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746730915_0.png" alt="eps graph" /></p>
<h3>Ocugen Share Price Analysis</h3>
<p>Shares of Ocugen were trading at $0.6621 as of May 07. Over the last 52-week period, shares are down 56.46%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. </p>
<h3>Analyst Insights on Ocugen</h3>
<p>Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Ocugen.</p>
<p>The consensus rating for Ocugen is Buy, derived from 4 analyst ratings. An average one-year price target of $7.25 implies a potential 995.0% upside.</p>
<h3>Peer Ratings Overview</h3>
<p>The analysis below examines the analyst ratings and average 1-year price targets of  and Y-mAbs Therapeutics, three significant industry players, providing valuable insights into their relative performance expectations and market positioning.</p>
<h3>Peer Analysis Summary</h3>
<p>Within the peer analysis summary, vital metrics for  and Y-mAbs Therapeutics are presented, shedding light on their respective standings within the industry and offering valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Y-mAbs Therapeutics</td>
<td>Buy</td>
<td>13.41%</td>
<td>$18.65M</td>
<td>-7.36%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Ocugen ranks at the bottom for Revenue Growth and Gross Profit among its peers. It is also at the bottom for Return on Equity. The Consensus rating for Ocugen is not provided for comparison.</p>
<h3>Delving into Ocugen's Background</h3>
<p>Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").</p>
<h3>Breaking Down Ocugen's Financial Performance</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.</p>
<p><strong>Revenue Growth:</strong> Ocugen's revenue growth over a period of 3 months has faced challenges. As of 31 December, 2024, the company experienced a revenue decline of approximately <strong>-45.78%</strong>. This indicates a decrease in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> Ocugen's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of <strong>-1816.75%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Ocugen's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of <strong>-39.51%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Ocugen's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of <strong>-19.23%,</strong> the company may encounter challenges in delivering satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> Ocugen's debt-to-equity ratio is notably higher than the industry average. With a ratio of <b>1.1</b>, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.</p>
<p><a href="https://www.benzinga.com/quote/OCGN/earnings"><strong>To track all earnings releases for Ocugen visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Earnings

OCGN

A Look at Ocugen's Upcoming Earnings Report

<p>UBS  analyst Kevin Caliendo   maintains American Well (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMWL#NYSE">AMWL</a>) with a Neutral and lowers the price target from $12 to $9.</p>


AMWL

UBS Maintains Neutral on American Well, Lowers Price Target to $9

<p>SiTime (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SITM#NASDAQ">SITM</a>) has been analyzed by 4 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.</p>
<p>The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Insights from analysts' 12-month price targets are revealed, presenting an average target of $158.75, a high estimate of $210.00, and a low estimate of $110.00. A decline of 14.19% from the prior average price target is evident in the current average. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746730876_0.png" alt="price target chart" /></p>
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
<p>An in-depth analysis of recent analyst actions unveils how financial experts perceive SiTime. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tom O'Malley</td>
<td>Barclays</td>
<td>Raises</td>
<td>Underweight</td>
<td>$135.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Tore Svanberg</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$210.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Tom O'Malley</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$110.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Tore Svanberg</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$180.00</td>
<td>$270.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to SiTime. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of SiTime compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts predict movements in price targets, offering estimates for SiTime's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Capture valuable insights into SiTime's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/SITM/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on SiTime analyst ratings.</strong></a></p>
<h2>Get to Know SiTime Better</h2>
<p>SiTime Corp is a provider of silicon timing systems solutions. The company designs develops and sell silicon timing systems solutions for different industries including automotive, infrastructure, aerospace-defense, consumer, internet of things, consumer and industrials. Its product offerings include Stratum 3E DCOCXOs, Programmable OCXOs, MHz Oscillators, 32.768 kHz Oscillators, Embedded Resonators, Precision MHz Super-TCXOs, and Ruggedized Oscillators. It sells its products around Taiwan, Hong Kong, the United States, and other regions and generates the majority of its revenue from Taiwan.</p>
<h3>SiTime's Financial Performance</h3>
<p><strong>Market Capitalization Perspectives:</strong> The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.</p>
<p><strong>Revenue Growth:</strong> Over the 3M period, SiTime showcased positive performance, achieving a revenue growth rate of <strong>60.63%</strong> as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Information Technology sector.</p>
<p><strong>Net Margin:</strong> SiTime's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>-27.62%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> SiTime's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>-2.7%</strong> ROE, the company effectively utilizes shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> SiTime's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of <strong>-2.13%,</strong> the company showcases efficient use of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>0.01</strong>, SiTime adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<h2>What Are Analyst Ratings?</h2>
<p>Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


SITM

Deep Dive Into SiTime Stock: Analyst Perspectives (4 Ratings)

<p>During the last three months, 9 analysts shared their evaluations of Leidos Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LDOS#NYSE">LDOS</a>), revealing diverse outlooks from bullish to bearish.</p>
<p>The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Insights from analysts' 12-month price targets are revealed, presenting an average target of $173.89, a high estimate of $200.00, and a low estimate of $155.00. Experiencing a 0.38% decline, the current average is now lower than the previous average price target of $174.56. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746730866_0.png" alt="price target chart" /></p>
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
<p>The perception of Leidos Holdings by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Matthew Akers</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$200.00</td>
<td>$173.00</td>
</tr>
<tr>
<td>Ken Herbert</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$160.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>Gavin Parsons</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$168.00</td>
<td>$149.00</td>
</tr>
<tr>
<td>Tobey Sommer</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$155.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>Matthew Akers</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$173.00</td>
<td>$191.00</td>
</tr>
<tr>
<td>Matthew Akers</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$191.00</td>
<td>$197.00</td>
</tr>
<tr>
<td>Tobey Sommer</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$165.00</td>
<td>$185.00</td>
</tr>
<tr>
<td>Gavin Parsons</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$156.00</td>
<td>$162.00</td>
</tr>
<tr>
<td>Matthew Akers</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$197.00</td>
<td>$199.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Leidos Holdings. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Leidos Holdings compared to the broader market.</li>
<li><strong>Price Targets:</strong> Gaining insights, analysts provide estimates for the future value of Leidos Holdings's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Leidos Holdings's market standing. Stay informed and make well-considered decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/LDOS/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Leidos Holdings analyst ratings.</strong></a></p>
<h2>About Leidos Holdings</h2>
<p>Leidos Holdings Inc is a technology, engineering, and science company that provides services and solutions in the defense, intelligence, civil, and health markets, both domestically and internationally. Company customer includes the U.S. Department of Defense ("DoD"), the U.S. Intelligence Community, the U.S. Department of Homeland Security ("DHS"), the Federal Aviation Administration ("FAA"), the Department of Veterans Affairs ("VA"), and many other U.S. civilian, state and local government agencies, etc. The company is engaged in four reportable segments; National Security &amp; Digital, Health &amp; Civil, Commercial &amp; International and Defense Systems. It provides a wide array of scientific, engineering and technical services and solutions across these reportable segments.</p>
<h3>Leidos Holdings's Economic Impact: An Analysis</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.</p>
<p><strong>Revenue Growth:</strong> Leidos Holdings's revenue growth over a period of 3M has been noteworthy. As of 31 March, 2025, the company achieved a revenue growth rate of approximately <strong>6.79%</strong>. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Industrials sector.</p>
<p><strong>Net Margin:</strong> Leidos Holdings's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>8.55%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> Leidos Holdings's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of <strong>8.37%,</strong> the company may face hurdles in generating optimal returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Leidos Holdings's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>2.76%</strong> ROA, the company effectively utilizes its assets for optimal returns.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>1.35</strong>, Leidos Holdings adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<h2>Analyst Ratings: Simplified</h2>
<p>Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.</p>
<p>Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


LDOS

Leidos Holdings Stock: A Deep Dive Into Analyst Perspectives (9 Ratings)

<p>High-rolling investors have positioned themselves bullish on Energy Transfer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ET#NYSE">ET</a>), and it's important for retail traders to take note.<br />
\This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in ET often signals that someone has privileged information.</p>
<p>Today, Benzinga's options scanner spotted 9 options trades for Energy Transfer. This is not a typical pattern.</p>
<p>The sentiment among these major traders is split, with 77% bullish and 22% bearish. Among all the options we identified, there was one put, amounting to $37,212, and 8 calls, totaling $314,340.</p>
<h3>Projected Price Targets</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $10.0 to $22.0 for Energy Transfer over the recent three months. </p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.</p>
<p>This data can help you track the liquidity and interest for Energy Transfer's options for a given strike price.</p>
<p>Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Energy Transfer's whale activity within a strike price range from $10.0 to $22.0 in the last 30 days. </p>
<h3>Energy Transfer Call and Put Volume: 30-Day Overview</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746730860_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>ET</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>10/17/25</td>
<td>$7.2</td>
<td>$6.2</td>
<td>$7.0</td>
<td>$10.00</td>
<td>$56.0K</td>
<td>93</td>
<td>0</td>
</tr>
<tr>
<td>ET</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>07/18/25</td>
<td>$0.44</td>
<td>$0.41</td>
<td>$0.44</td>
<td>$18.00</td>
<td>$44.1K</td>
<td>5.3K</td>
<td>4.8K</td>
</tr>
<tr>
<td>ET</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$0.52</td>
<td>$0.49</td>
<td>$0.5</td>
<td>$20.00</td>
<td>$40.0K</td>
<td>39.8K</td>
<td>1.2K</td>
</tr>
<tr>
<td>ET</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$2.07</td>
<td>$1.69</td>
<td>$1.98</td>
<td>$17.00</td>
<td>$39.6K</td>
<td>18.9K</td>
<td>0</td>
</tr>
<tr>
<td>ET</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$0.78</td>
<td>$0.71</td>
<td>$0.78</td>
<td>$22.00</td>
<td>$39.0K</td>
<td>39.1K</td>
<td>1.6K</td>
</tr>
</tbody>
</table>
</p>
<h3>About Energy Transfer</h3>
<p>Energy Transfer owns one of the largest portfolios of crude oil, natural gas, and natural gas liquid assets in the US, primarily in Texas and the US midcontinent region. Its pipeline network includes more than 12,000 miles of intrastate pipelines and 20,000 miles of interstate pipelines. It also owns gathering, processing, and storage facilities in the largest US oil and gas producing regions. Other businesses include a network of natrual gas liquids and refined products facilities, 18,000 miles of crude oil pipelines, and the Lake Charles gas liquefaction facility. Energy Transfer combined its publicly traded limited and general partnerships in October 2018.</p>
<h3>Energy Transfer's Current Market Status</h3>
<ul>
<li>With a trading volume of 13,849,968, the price of ET is up by 3.2%, reaching $17.43.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 90 days from now.</li>
</ul>
<h3>Professional Analyst Ratings for Energy Transfer</h3>
<p>1 market experts have recently issued ratings for this stock, with a consensus target price of $21.0.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Wells Fargo has decided to maintain their Overweight rating on Energy Transfer, which currently sits at a price target of $21. </p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Energy Transfer with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.</p>


Options

Markets

Unpacking the Latest Options Trading Trends in Energy Transfer

<p>Investors with significant funds have taken a bullish position in McKesson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCK#NYSE">MCK</a>), a development that retail traders should be aware of.</p>
<p>This was brought to our attention today through our monitoring of publicly accessible options data at Benzinga. The exact nature of these investors remains a mystery, but such a major move in MCK usually indicates foreknowledge of upcoming events.</p>
<p>Today, Benzinga's options scanner identified 8 options transactions for McKesson. This is an unusual occurrence. The sentiment among these large-scale traders is mixed, with 37% being bullish and 37% bearish. Of all the options we discovered, 7 are puts, valued at $420,706, and there was a single call, worth $48,840.</p>
<h3>Projected Price Targets</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $670.0 and $720.0 for McKesson, spanning the last three months.</p>
<h3>Insights into Volume &amp; Open Interest</h3>
<p>In today's trading context, the average open interest for options of McKesson stands at 29.83, with a total volume reaching 329.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in McKesson, situated within the strike price corridor from $670.0 to $720.0, throughout the last 30 days.</p>
<h3>McKesson Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746730854_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th align="right"><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>MCK</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>05/23/25</td>
<td>$17.5</td>
<td>$16.3</td>
<td>$16.3</td>
<td>$690.00</td>
<td>$104.3K</td>
<td align="right">9</td>
<td align="right">64</td>
</tr>
<tr>
<td>MCK</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>06/06/25</td>
<td>$33.7</td>
<td>$30.3</td>
<td>$32.0</td>
<td>$720.00</td>
<td>$83.2K</td>
<td align="right">26</td>
<td align="right">26</td>
</tr>
<tr>
<td>MCK</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>05/09/25</td>
<td>$19.1</td>
<td>$18.7</td>
<td>$18.7</td>
<td>$705.00</td>
<td>$72.9K</td>
<td align="right">10</td>
<td align="right">88</td>
</tr>
<tr>
<td>MCK</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>05/09/25</td>
<td>$18.3</td>
<td>$17.2</td>
<td>$18.3</td>
<td>$705.00</td>
<td>$67.7K</td>
<td align="right">10</td>
<td align="right">47</td>
</tr>
<tr>
<td>MCK</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>05/09/25</td>
<td>$11.1</td>
<td>$7.0</td>
<td>$11.1</td>
<td>$720.00</td>
<td>$48.8K</td>
<td align="right">114</td>
<td align="right">71</td>
</tr>
</tbody>
</table>
</p>
<h3>About McKesson</h3>
<p>McKesson Corp is one of three leading pharmaceutical wholesalers in the us engaged in sourcing and distributing branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with Cencora and Cardinal Health, the three account for over 90% of the us pharmaceutical wholesale industry. Outside the us market, McKesson engages in pharmaceutical wholesale and distribution in Canada. Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.</p>
<p>In light of the recent options history for McKesson, it's now appropriate to focus on the company itself. We aim to explore its current performance.</p>
<h3>McKesson's Current Market Status</h3>
<ul>
<li>Trading volume stands at 980,284, with MCK's price down by -2.78%, positioned at $702.25.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 0 days.</li>
</ul>
<h3>What The Experts Say On McKesson</h3>
<p>Over the past month, 2 industry analysts have shared their insights on this stock, proposing an average target price of $780.0.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; Consistent in their evaluation, an analyst from UBS keeps a Buy rating on McKesson with a target price of $805.<br />
&#x2A; An analyst from B of A Securities persists with their Buy rating on McKesson, maintaining a target price of $755. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for McKesson, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.</p>


McKesson Unusual Options Activity

<p>Ratings for Bunge Global (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BG#NYSE">BG</a>) were provided by 4 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.</p>
<p>The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets, analyzed by analysts, offer insights with an average target of $80.75, a high estimate of $87.00, and a low estimate of $74.00. A decline of 10.53% from the prior average price target is evident in the current average. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746730853_0.png" alt="price target chart" /></p>
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
<p>The standing of Bunge Global among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pooran Sharma</td>
<td>Stephens &amp; Co.</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$85.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Thomas Palmer</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$77.00</td>
<td>$76.00</td>
</tr>
<tr>
<td>Vincent Andrews</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$74.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Steve Byrne</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$87.00</td>
<td>$105.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Bunge Global. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Bunge Global compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts navigate through adjustments in price targets, providing estimates for Bunge Global's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Bunge Global's market position. Stay informed and make well-informed decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/BG/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Bunge Global analyst ratings.</strong></a></p>
<h2>Unveiling the Story Behind Bunge Global</h2>
<p>Bunge Global SA formerly Bunge Ltd is an agribusiness and food company with operations along the farm-to-consumer food chain. The company segments include Agribusiness; Refined and Specialty Oils; Milling; Sugar and Bioenergy and Corporate and Other. It generates maximum revenue from the Agribusiness segment. The company is an oilseed processor and producer of vegetable oils and protein meals, based on processing capacity, a grain processor, the seller of packaged plant-based oils, producer and seller of wheat flour, bakery mixes and corn-based products in North and South America.</p>
<h3>Bunge Global's Economic Impact: An Analysis</h3>
<p><strong>Market Capitalization Analysis:</strong> With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.</p>
<p><strong>Negative Revenue Trend:</strong> Examining Bunge Global's financials over 3M reveals challenges. As of 31 December, 2024, the company experienced a decline of approximately <strong>-9.33%</strong> in revenue growth, reflecting a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Consumer Staples sector.</p>
<p><strong>Net Margin:</strong> Bunge Global's net margin is impressive, surpassing industry averages. With a net margin of <strong>4.45%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Bunge Global's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>6.01%</strong> ROE, the company effectively utilizes shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of <strong>2.4%,</strong> the company showcases effective utilization of assets.</p>
<p><strong>Debt Management:</strong> Bunge Global's debt-to-equity ratio surpasses industry norms, standing at <strong>0.72</strong>. This suggests the company carries a substantial amount of debt, posing potential financial challenges.</p>
<h2>Understanding the Relevance of Analyst Ratings</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Expert Outlook: Bunge Global Through The Eyes Of 4 Analysts

<p>Deep-pocketed investors have adopted a bearish approach towards MercadoLibre (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MELI#NASDAQ">MELI</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in MELI usually suggests something big is about to happen.</p>
<p>We gleaned this information from our observations today when Benzinga's options scanner highlighted 121 extraordinary options activities for MercadoLibre. This level of activity is out of the ordinary.</p>
<p>The general mood among these heavyweight investors is divided, with 31% leaning bullish and 37% bearish. Among these notable options, 19 are puts, totaling $1,016,536, and 102 are calls, amounting to $18,549,592.</p>
<h3>What's The Price Target?</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $1020.0 to $3100.0 for MercadoLibre over the recent three months. </p>
<h3>Volume &amp; Open Interest Development</h3>
<p>Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for MercadoLibre's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of MercadoLibre's whale trades within a strike price range from $1020.0 to $3100.0 in the last 30 days. </p>
<h3>MercadoLibre Call and Put Volume: 30-Day Overview</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746730849_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th align="right"><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>MELI</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$747.5</td>
<td>$746.0</td>
<td>$746.0</td>
<td>$1800.00</td>
<td>$1.4M</td>
<td align="right">165</td>
<td align="right">110</td>
</tr>
<tr>
<td>MELI</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>05/09/25</td>
<td>$174.0</td>
<td>$168.1</td>
<td>$168.1</td>
<td>$2250.00</td>
<td>$235.3K</td>
<td align="right">127</td>
<td align="right">84</td>
</tr>
<tr>
<td>MELI</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$310.6</td>
<td>$305.7</td>
<td>$305.7</td>
<td>$2190.00</td>
<td>$183.4K</td>
<td align="right">4</td>
<td align="right">7</td>
</tr>
<tr>
<td>MELI</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>05/16/25</td>
<td>$225.9</td>
<td>$210.0</td>
<td>$217.55</td>
<td>$2200.00</td>
<td>$108.8K</td>
<td align="right">37</td>
<td align="right">17</td>
</tr>
<tr>
<td>MELI</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>12/19/25</td>
<td>$207.0</td>
<td>$192.0</td>
<td>$200.1</td>
<td>$2700.00</td>
<td>$100.0K</td>
<td align="right">1</td>
<td align="right">15</td>
</tr>
</tbody>
</table>
</p>
<h3>About MercadoLibre</h3>
<p>MercadoLibre runs the largest e-commerce marketplace in Latin America, with more than 218 million active users and 1 million active sellers across 18 countries stitching into its commerce network or fintech solutions when last reported. The company operates a host of complementary businesses to its core online shop, with shipping solutions (Mercado Envios), a payment and financing operation (Mercado Pago and Mercado Credito), advertisements (Mercado Clics), classifieds, and a turnkey e-commerce solution (Mercado Shops) rounding out its arsenal. MercadoLibre generates revenue from final value fees, advertising royalties, payment processing, insertion fees, subscription fees, and interest income from consumer and small-business lending.</p>
<p>In light of the recent options history for MercadoLibre, it's now appropriate to focus on the company itself. We aim to explore its current performance.</p>
<h3>Present Market Standing of MercadoLibre</h3>
<ul>
<li>With a volume of 669,375, the price of MELI is up 6.2% at $2402.26. </li>
<li>RSI indicators hint that the underlying stock may be overbought.</li>
<li>Next earnings are expected to be released in 84 days.</li>
</ul>
<h3>Expert Opinions on MercadoLibre</h3>
<p>4 market experts have recently issued ratings for this stock, with a consensus target price of $2640.0.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; Consistent in their evaluation, an analyst from Morgan Stanley keeps a Overweight rating on MercadoLibre with a target price of $2560.<br />
&#x2A; Reflecting concerns, an analyst from Benchmark lowers its rating to Buy with a new price target of $2500.<br />
&#x2A; Maintaining their stance, an analyst from Cantor Fitzgerald continues to hold a Overweight rating for MercadoLibre, targeting a price of $2400.<br />
&#x2A; Maintaining their stance, an analyst from Barclays continues to hold a Overweight rating for MercadoLibre, targeting a price of $3100. </p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for MercadoLibre with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.</p>


MELI

Check Out What Whales Are Doing With MELI

Press Releases

Harmony Biosciences to Participate in Upcoming Investor Conferences

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harmony Biosciences Holdings, Inc. - HRMY

HRMY Investors Have Opportunity to Join Harmony Biosciences Holdings, Inc. Fraud Investigation with the Schall Law Firm

Harmony Biosciences Names Adam Zaeske as Chief Commercial Officer to Lead the Next Phase of Commercial Growth as Its Portfolio Expands

Harmony Biosciences to Participate in 24th Annual Needham Virtual Healthcare Conference

Harmony Biosciences Appoints Biotech Leader Ron Philip to Its Board of Directors

Harmony Biosciences Presents Promising Open-Label Extension Data of ZYN002 in Fragile X Syndrome

Harmony Biosciences to Report First Quarter 2025 Financial Results on May 6, 2025

Harmony Biosciences Reports Strong Q1 2025 Financial Results, Highlights Advancement of Its Pipeline and Upcoming Catalysts, and Reaffirms 2025 Revenue Guidance ​

Comments

Harmony Biosciences Hldgs

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO